ETON · NASDAQ
Eton Pharmaceuticals (ETON) Stock Price & Fundamentals
Eton Pharmaceuticals (ETON) closed at $464.91 on Oct 9, 2026, down 0.23% from the previous close of $465.98.
Share price, past year
1Y +9.04%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $464.91 |
| Sep 30, 2026 | $457.33 |
| Aug 31, 2026 | $423.26 |
| Jul 31, 2026 | $409.15 |
| Jun 30, 2026 | $396.40 |
| May 29, 2026 | $422.09 |
| Apr 30, 2026 | $395.35 |
| Mar 31, 2026 | $406.67 |
| Feb 27, 2026 | $431.46 |
| Jan 30, 2026 | $447.05 |
| Dec 31, 2025 | $429.66 |
| Nov 28, 2025 | $440.57 |
| Oct 31, 2025 | $421.47 |
Key statistics
- Market cap
- $13.15B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $105.60M
- Net income (TTM)
- $12.69M
- Shares outstanding
- 28.3M
- Dividend yield
- —
- 52-week range
- $371.59 – $466.62
Eton Pharmaceuticals's market cap is $13.15B, based on a share price of $464.91 and 28.3M shares outstanding as of Jun 30, 2026.
Financials
Eton Pharmaceuticals reported revenue of $79.95M for fiscal 2025, up 104.94% from fiscal 2024.
Eton Pharmaceuticals reported a net loss of $4.60M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $79.95M | +104.9% | −$4.60M | −5.8% | — | $10.19M |
| FY2024ended Dec 31, 2024 | $39.01M | +23.3% | −$3.82M | −9.8% | — | $943.00K |
| FY2023ended Dec 31, 2023 | $31.64M | +48.9% | −$936.00K | −3.0% | — | $6.82M |
| FY2022ended Dec 31, 2022 | $21.25M | −2.7% | −$9.02M | −42.5% | — | $4.78M |
| FY2021ended Dec 31, 2021 | $21.83M | +55,879.5% | −$1.96M | −9.0% | −$0.08 | −$4.73M |
| FY2020ended Dec 31, 2020 | $39.00K | −95.9% | −$27.97M | −71,718.0% | −$1.33 | −$22.40M |
| FY2019ended Dec 31, 2019 | $959.00K | — | −$18.32M | −1,910.3% | −$1.03 | −$19.12M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $37.59M | $11.58M | $0.35 |
| Q1 FY2026ended Mar 31, 2026 | $24.27M | $1.55M | $0.05 |
| Q4 FY2025ended Dec 31, 2025 | $21.28M | $1.48M | — |
| Q3 FY2025ended Sep 30, 2025 | $22.46M | −$1.93M | −$0.07 |
| Q2 FY2025ended Jun 30, 2025 | $18.93M | −$2.59M | −$0.10 |
| Q1 FY2025ended Mar 31, 2025 | $17.28M | −$1.57M | −$0.06 |
| Q4 FY2024ended Dec 31, 2024 | $11.65M | −$598.00K | — |
| Q3 FY2024ended Sep 30, 2024 | $10.32M | $627.00K | $0.02 |
Company profile
- Name
- Eton Pharmaceuticals, Inc.
- Ticker
- ETON
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 21925 W. Field Parkway, Suite 235, Deer Park, IL 60010-7278
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001710340
Recent SEC filings
- Sep 28, 2026
- Aug 13, 2026
- Aug 13, 2026
- Aug 5, 2026
- Aug 4, 2026
- Jul 29, 2026
- Jun 9, 2026
- May 19, 2026
Frequently asked questions
What is Eton Pharmaceuticals's stock price?
Eton Pharmaceuticals (ETON) closed at $464.91 on Oct 9, 2026, down 0.23% from the previous close of $465.98.
What is Eton Pharmaceuticals's market cap?
Eton Pharmaceuticals's market cap is $13.15B, based on a share price of $464.91 and 28.3M shares outstanding as of Jun 30, 2026.
How much revenue does Eton Pharmaceuticals make?
Eton Pharmaceuticals reported revenue of $79.95M for fiscal 2025, up 104.94% from fiscal 2024.
Does Eton Pharmaceuticals pay a dividend?
Eton Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Eton Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures